Ozempic Shortage 2026 Supply Update and Alternatives
Ozempic Shortage 2026: Supply Update, Alternatives, and Your Action Plan
The GLP-1 landscape has shifted dramatically since the shortages began in 2023. As of May 2026, the Ozempic shortage is far from resolved, and providers must navigate a complex patchwork of supply constraints, regulatory shifts, and emerging alternatives. This guide delivers the specific data, switching protocols, and strategic foresight you need to keep your patients on track through Q4 2026 and beyond.
We cover the current FDA shortage status, the most effective alternatives including tirzepatide and compounded semaglutide, practical dosing equivalencies, and the critical regulatory deadline every provider must address before May 2026. If you are managing patients dependent on Ozempic, the decisions you make now will determine whether they maintain progress or face treatment disruption.
Current FDA Shortage Status: Where We Stand in May 2026
As of January 2026, the FDA Drug Shortages Database lists Ozempic 1 mg and 2 mg doses as still in shortage. Wegovy all doses are available except the 0.25 mg starter dose. This marks a slight improvement from late 2025, when all Ozempic doses were constrained, but it is far from a full recovery.
Novo Nordisk has invested heavily in production capacity. The company reports a 2026 production capacity of 40 million monthly doses, up from 25 million in 2024. However, demand has surged faster than supply. Estimated monthly demand for semaglutide (Ozempic plus Wegovy) is projected to reach 55 million monthly doses by June 2026. This 15 million dose gap means that even with expanded production, new prescriptions will face delays of 4 to 8 weeks for the foreseeable future.
The FDA has not issued a formal resolution date. Based on current manufacturing expansion timelines and demand projections, most industry analysts expect the shortage to persist through at least Q4 2026. Some doses may see intermittent availability, but consistent supply for all patients is unlikely before early 2027.
The Compounder Loophole Is Closing: A May 2026 Deadline
This is the critical angle most articles miss. Compounded semaglutide has been a lifeline for patients unable to access brand-name Ozempic. However, the FDA is expected to issue final guidance in April 2026 that will restrict compounded semaglutide to only patients with a documented allergy or intolerance to the brand drug.
This guidance, once finalized, will effectively close the “shortage loophole” that has allowed compounding pharmacies to produce large quantities of semaglutide. After the guidance takes effect, providers will need to document medical necessity for compounded use—specifically, a contraindication to the brand product—or transition patients to FDA-approved alternatives.
Actionable advice: Begin now to document each patient’s medical history. If a patient has experienced nausea, vomiting, or injection site reactions with brand Ozempic, record this explicitly in the chart. If you plan to continue using compounded semaglutide beyond May 2026, you need a clear clinical rationale. For all other patients, start the transition to an alternative GLP-1 or dual agonist now, rather than waiting for the shortage to force a rushed switch.
Approved GLP-1 Alternatives to Ozempic in 2026
Several FDA-approved alternatives are available, each with distinct efficacy, cost, and supply profiles. The table below provides a side-by-side comparison to guide your prescribing decisions.
| Drug Name | Active Ingredient | Dosing Frequency | Average Monthly Cost (Cash) | Typical Weight Loss at 6 Months | FDA Shortage Status (May 2026) | Insurance Coverage Likelihood |
|---|---|---|---|---|---|---|
| Ozempic | Semaglutide | Weekly | $935–$1,349 | 10–15% | 1 mg & 2 mg in shortage | High (T2D); Moderate (weight loss off-label) |
| Wegovy | Semaglutide | Weekly | $1,350–$1,600 | 12–16% | All doses available except 0.25 mg | Moderate (weight loss indication) |
| Mounjaro / Zepbound | Tirzepatide | Weekly | $1,020–$1,300 | 15–22% | No shortage (all doses available) | High (T2D & weight loss) |
| Saxenda | Liraglutide | Daily | $1,200–$1,500 | 6–8% | No shortage | Moderate (weight loss) |
| Trulicity | Dulaglutide | Weekly | $850–$1,100 | 5–7% | No shortage | High (T2D only) |
| Compounded Semaglutide | Semaglutide (non-brand) | Weekly | $150–$300 | Variable (8–14% in studies) | Available now; restricted after May 2026 | Low (typically cash pay) |
Key takeaway: Tirzepatide (Mounjaro/Zepbound) offers the highest efficacy for both weight loss and glycemic control, with no current shortage. It is the strongest alternative for patients who need uninterrupted treatment.
Switching Protocols: From Ozempic to Alternatives
Transitioning patients from Ozempic to another GLP-1 requires careful dosing to minimize side effects and maintain progress. Below is a practical switching framework based on your patient’s current Ozempic dose.
Switching from Ozempic to Mounjaro/Zepbound (Tirzepatide)
| Current Ozempic Dose | Starting Mounjaro/Zepbound Dose | Titration Schedule | Washout Period |
|---|---|---|---|
| 0.25 mg weekly | 2.5 mg weekly | Stay on 2.5 mg for 4 weeks, then increase to 5 mg | None needed (same-day switch is safe) |
| 0.5 mg weekly | 2.5 mg weekly | Stay on 2.5 mg for 4 weeks, then increase to 5 mg | None needed |
| 1.0 mg weekly | 5.0 mg weekly | Stay on 5 mg for 4 weeks, then increase to 7.5 mg if tolerated | Consider 1-week washout to reduce nausea risk |
| 2.0 mg weekly | 5.0 mg weekly | Stay on 5 mg for 4 weeks, then increase to 7.5 mg, then 10 mg | 1-week washout recommended |
Real-world data from Truveta (2025) shows that 78% of patients who transitioned from Ozempic to Mounjaro maintained greater than 80% of their weight loss at 6 months. This is a strong endorsement for the switch, especially given Mounjaro’s superior efficacy in the SURMOUNT-1 trial: 22.5% average weight loss at 72 weeks versus 15.8% for semaglutide in STEP-1.
Switching from Ozempic to Compounded Semaglutide
If you choose to use compounded semaglutide before the May 2026 deadline, the transition is straightforward because the active ingredient is identical. Use a 1:1 dose conversion. For example, a patient on Ozempic 1 mg weekly can start compounded semaglutide at 1 mg weekly. No washout is needed.
However, be aware that compounded semaglutide is not FDA-approved for safety, efficacy, or sterility. The FDA has issued multiple warnings about adverse events linked to compounded GLP-1s, including dosing errors and contamination. Document informed consent explicitly.
Switching from Ozempic to Saxenda (Liraglutide)
Saxenda is dosed daily, which may reduce adherence. The starting dose is 0.6 mg daily for one week, then titrated weekly by 0.6 mg to a maximum of 3.0 mg daily. Because Saxenda is less potent, patients switching from Ozempic 1 mg or higher may experience a temporary plateau or slight weight regain. A 1- to 2-week washout is recommended to reset tolerance.
Decision Matrix: Should Your Patient Switch or Wait?
Use the following framework to guide patient conversations. The decision hinges on two variables: the patient’s urgency for immediate supply and their insurance coverage.
| Patient Profile | Insurance Covers Brand Alternative | Insurance Covers Compounded Only | No Insurance Coverage |
|---|---|---|---|
| Urgent need (cannot wait 4–8 weeks) | Switch to Mounjaro/Zepbound (best efficacy, no shortage) | Try compounded semaglutide now, but plan transition by May 2026 | Consider compounded semaglutide or micro-dosing Mounjaro (see below) |
| Can wait 4–8 weeks | Wait for Ozempic restock, but have backup plan | Wait for Ozempic restock; compounded is a short-term bridge | Wait for Ozempic restock or explore patient assistance programs |
| Stable on current dose, no immediate supply gap | Continue current plan; monitor supply monthly | Continue compounded; prepare documentation for May 2026 | Continue current plan; consider long-term switch to Mounjaro |
Micro-Dosing from Mounjaro Pens: A Legal and Practical Guide
A strategy gaining traction among providers is micro-dosing from Mounjaro/Zepbound pens. This involves using a 15 mg pen to deliver a lower weekly dose (e.g., 5 mg) by splitting the pen’s contents across multiple injections. This can stretch a single pen to last three weeks instead of one, reducing monthly cost from $1,300 to roughly $430.
Practical protocol: The Mounjaro KwikPen delivers 0.5 mL of solution. A 15 mg pen contains 30 mg/mL, so each 0.5 mL dose delivers 15 mg. To obtain a 5 mg dose, you would need to administer 0.17 mL. This requires using an insulin syringe with 0.5 mL or 1 mL capacity to withdraw the correct volume.
Sterility concerns: The pen is designed for single-use. Reusing it increases infection risk. Providers should instruct patients to use a new sterile needle for each withdrawal, store the pen in the refrigerator after first use, and discard any unused solution after 28 days.
Legal risks: Splitting pens is off-label use. The FDA has not approved this practice, and state pharmacy boards in states like California, Texas, and New York have issued warnings. Providers who recommend this should document the rationale—such as cost savings or supply constraints—and obtain signed informed consent. Malpractice coverage may also be affected, so check with your carrier.
For patients who cannot afford brand alternatives and lack insurance, micro-dosing may be the most practical option. But it carries real liability. Weigh the risks carefully.
Side Effect Profiles: What to Expect When Switching
Understanding side effect differences helps you set patient expectations and manage tolerability during transitions.
| Side Effect | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) | Compounded Semaglutide |
|---|---|---|---|
| Nausea (any severity) | 44% (STEP-1 trial) | 30–35% (SURMOUNT-1 trial) | Variable (reports of 25–50% due to variability in purity) |
| Vomiting | 24% | 15–20% | 15–30% (depends on compounding pharmacy) |
| Diarrhea | 30% | 22–28% | 20–35% |
| Injection site reactions | 3–5% | 5–8% | 5–15% (higher due to variable excipients) |
Tirzepatide generally shows a lower rate of gastrointestinal side effects compared to semaglutide, which may improve adherence during the switch. However, patients transitioning from high-dose Ozempic (2 mg) to Mounjaro 5 mg may still experience nausea due to the potency change. Starting at 2.5 mg and titrating slowly is recommended for sensitive patients.
Cost Comparison and Insurance Coverage in 2026
Cash prices for brand GLP-1s remain high. Without insurance, Ozempic costs $935 to $1,349 per month. Mounjaro and Zepbound are similar, at $1,020 to $1,300. Compounded semaglutide is significantly cheaper at $150 to $300 per month, but this option may disappear after May 2026.
Insurance coverage varies widely. For type 2 diabetes, most plans cover Ozempic, Mounjaro, and Trulicity. For weight loss, coverage is less consistent. Wegovy and Zepbound are often covered, but prior authorization may require a BMI of 30 or greater or 27 with a comorbidity. Compounded semaglutide is rarely covered by insurance, as it is not an FDA-approved product.
Actionable advice: Before switching a patient, run a drug coverage check. If their plan covers Mounjaro for weight loss, that is the most effective and sustainable alternative. If coverage is denied, consider appealing with documentation of the shortage and clinical necessity.
Frequently Asked Questions
Q: Is Ozempic still on the FDA shortage list in 2026?
A: Yes. As of January 2026, Ozempic 1 mg and 2 mg doses remain on the FDA shortage list. Wegovy is available except for the 0.25 mg starter dose. The shortage is expected to persist through at least Q4 2026.
Q: When will Ozempic be back in stock for new prescriptions?
A: Novo Nordisk has increased production to 40 million monthly doses, but demand is projected at 55 million monthly doses by June 2026. Consistent supply for new prescriptions is unlikely before early 2027. Existing patients may experience intermittent delays.
Q: What is the closest alternative to Ozempic that works as well?
A: Mounjaro/Zepbound (tirzepatide) is the closest and most effective alternative. It shows 22.5% average weight loss at 72 weeks compared to 15.8% for semaglutide. It is also not in shortage. Compounded semaglutide is chemically identical but faces regulatory restrictions after May 2026.
Q: Can I switch from Ozempic to Mounjaro or compounded semaglutide without losing progress?
A: Yes. Real-world data shows 78% of patients maintain greater than 80% of weight loss at 6 months after switching from Ozempic to Mounjaro. For compounded semaglutide, the switch is 1:1, so progress is typically maintained. A 1-week washout is recommended for high-dose Ozempic patients to reduce nausea.
Q: Are compounded versions of semaglutide safe and FDA-approved?
A: Compounded semaglutide is not FDA-approved for safety, efficacy, or sterility. The FDA has issued warnings about adverse events. It is only legally available during the shortage. After May 2026, it will be restricted to patients with documented allergy or intolerance to brand semaglutide.
Q: Will my insurance cover alternative GLP-1 drugs if Ozempic is unavailable?
A: Coverage depends on your plan. Most insurance covers Mounjaro for type 2 diabetes. For weight loss, Wegovy and Zepbound are often covered with prior authorization. Compounded semaglutide is rarely covered. Always check your formulary and consider an appeal if coverage is denied.
Your Next Steps as a Provider
The Ozempic shortage of 2026 is not a temporary blip. It is a structural supply-demand mismatch that will last through the end of the year. Providers who act now will protect their patients from treatment gaps and regulatory surprises.
First, assess each patient’s current supply. If they have less than 4 weeks of Ozempic remaining, initiate a switch to Mounjaro or Zepbound. Use the dosing table above to ensure a smooth transition. Second, document medical necessity for any patient using compounded semaglutide. The May 2026 FDA guidance will require this documentation, and you do not want to be caught unprepared. Third, consider micro-dosing only as a last resort, with full informed consent and awareness of legal risks.
The data is clear: tirzepatide offers superior outcomes, stable supply, and manageable side effects. For the majority of patients, switching now is the safest and most effective path forward. Do not wait for the shortage to resolve—it will not happen soon enough.